20 articles
NHLBI researchers optimize collection and storage of umbilical cord blood from sickle cell-affected and healthy newborns for future stem cell therapies.
A landmark effort to bank immune-compatible stem cells matched to the majority of the US population — now terminated.
Study evaluates umbilical cord and placental tissues for cost-effective mesenchymal stem cell banking and regenerative medicine applications.
NIDCR researchers compared stromal cells from bone marrow, skin, spleen, and fat to identify which best regenerates bone and supports blood formation.
Autologous stem cell injections tested in patients with severe leg circulation problems who had no surgical options.
Small trial tests safety of injecting patients' own cardiac stem cells to regrow dead heart tissue and restore function.
Large trial tests umbilical cord stem cells to prevent heart failure in heart attack patients with reduced heart function.
Researchers tested whether stem cells from healthy hearts could help repair damage in heart attack patients, offering hope for cardiac regeneration.
A Phase 1/2 trial tests four rounds of intrathecal MSC injections in ALS patients, targeting both safety and disease progression.
Researchers compared stem cells from arthritis patients versus healthy donors to assess regenerative therapy potential.
65-patient trial tested bone marrow stem cells injected directly into damaged heart muscle to restore function in chronic heart failure.
115-patient trial tested CardioCell stem cell treatment against placebo for chronic heart failure patients with promising regenerative approach.
Small trial tests autologous stem cells to regenerate damaged knee cartilage in osteoarthritis patients with promising safety profile.
Clinical trial tested whether bone marrow stem cells could improve heart function beyond standard bypass surgery alone.
Researchers tested injecting cardiac stem cells directly into heart arteries after heart attacks to promote healing and regeneration.
Austrian researchers tracked heart attack patients for 5 years after receiving bone marrow cell therapy to assess long-term cardiac outcomes.
Adipose-derived stem cells combined with platelet-rich plasma evaluated for treating moderate to severe knee osteoarthritis over 2 years.
Completed study tested regenerative cardiac therapy in 105 heart attack patients, comparing stem cell treatment to placebo controls.
32-person trial compared bone marrow stem cells, platelet therapy, and hyaluronic acid for knee arthritis treatment over one year.
Study shows intensive glucose management increases cardiac stem cells in heart attack patients, potentially improving recovery.
